title: Establishment and characterization of a new, factor-independent acute myeloid leukemia line designated Ei501.
abstract: We established a factor-independent acute myeloid leukemia cell line, designated Ei501. The line has been growing in RPMI 1640 media for 18 months and can be maintained without addition of growth factors. Ei501 is positive for myeloperoxidase and negative for esterase and PAS. Cytogenetic analysis revealed the FAB M3 associated t(15;17) translocation and a translocation of the chromosomes 7 and 8: 46 XX, -7, +t(7;8)(q32;q13), t(15;17)(q22;q12). This karyotype was confirmed by fluorescence in situ hybridization. Ei501 cells express AML-associated surface markers such as CD13, CD33 and CD38. Although 42% of the patient's blast cells were CD34-positive, the line lacks surface expression of CD34. Furthermore the line has a number of characteristics which are detectable in blasts from AML patients, such as surface adhesion molecules, cytokines such as TGF-beta, cytokine receptors such as the IL-2 receptor beta and gamma chains or the IL-4 receptor and the genes for the transcription factor wt-1 (Wilms' tumor gene) and for the proto-oncogene bcl-2, both shown to be present in the majority of patients with AML. Additionally the line can be used as target in cytotoxicity assays using IL-2 activated cytotoxic lymphocytes as effector cells. In conclusion, besides a rare karyotype the Ei501 cell line has several features common in AML, and may therefore be used as a model to study pathogenetic mechanisms in acute myeloid leukemia.
authors.affiliation: Medical Clinic III, Department of Internal Medicine, University Hospital, Johann-Wolfgang Goethe University, Frankfurt/M, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Weidmann
authors.forename: J
authors.initials: J
authors.lastname: Brieger
authors.forename: T
authors.initials: T
authors.lastname: Karakas
authors.forename: U
authors.initials: U
authors.lastname: Maurer
authors.forename: U
authors.initials: U
authors.lastname: Pascheberg
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
authors.forename: P S
authors.initials: PS
authors.lastname: Mitrou
authors.forename: L
authors.initials: L
authors.lastname: Bergmann
mesh_terms: D000293:Adolescent; D015703:Antigens, CD / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology; D002460:Cell Line; D002874:Chromosome Mapping; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D002897:Chromosomes, Human, Pair 7; D002898:Chromosomes, Human, Pair 8; D016207:Cytokines / Q000096:biosynthesis* / Q000235:genetics; D017931:DNA Primers; D005260:Female; D006680:HLA Antigens / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000276:immunology / Q000473:pathology*; D016133:Polymerase Chain Reaction; D000090063:Proto-Oncogene Mas; D014178:Translocation, Genetic; D014407:Tumor Cells, Cultured
chemical_list: D015703:Antigens, CD; D016207:Cytokines; D017931:DNA Primers; D006680:HLA Antigens; D006684:HLA-DR Antigens; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas